ReviewOphthalmology and therapy2020
The Role of Systemic Antimicrobials in the Treatment of Endophthalmitis: A Review and an International Perspective.
Review in Ophthalmology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Areas of uncertainty in endophthalmitis care.World journal of clinical cases · 2026Review
- Article
- Piperacillin/Tazobactam-Induced Bilateral Optic Disc Edema With Serous Retinal Fluid in a Young Female With Pelvic Abscess and Sepsis.Case reports in infectious diseases · 2026Article
- Article
- Clinical Roles of Infectious Diseases Specialists in Ophthalmology.Infectious diseases & clinical microbiology · 2025Article
- Bilateral endogenous fungal endophthalmitis following elective surgical abortion: a single center case series.Journal of ophthalmic inflammation and infection · 2025Article
- Ultrastructural and Immunohistochemical Study of Double and Combined Intravitreal Administration of Antifungal Agents in the Retina of New Zealand Albino Rabbits: An Experimental Protocol.Journal of fungi (Basel, Switzerland) · 2025Article
- Proteomic profiling reveals immunomodulatory role of IL-33 in ocular bacterial and fungal infections.Infection and immunity · 2025Article
- Article
- Controversies in the management of endophthalmitis: a 5-year retrospective cohort study.Journal of ophthalmic inflammation and infection · 2025Article
- Article
- The diagnosis and treatment progress of infectious endophthalmitis.Eye (London, England) · 2025Review
- Antibiotic susceptibility in Endophthalmitis Management Study and intravitreal antibiotic practice trend in India-EMS Report #5.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Literature- and Experience-Based Consensus for Acute Post-operative Endophthalmitis and Endogenous Endophthalmitis in Taiwan.Ophthalmology and therapy · 2024Article
- Management and Prognosis of Acute Post-Cataract Surgery Endophthalmitis: A 10-Year Retrospective Analysis in Eastern China.Antibiotics (Basel, Switzerland) · 2023Article
- Oral administration of S-nitroso-L-glutathione (GSNO) provides anti-inflammatory and cytoprotective effects during ocular bacterial infections.Cellular and molecular life sciences : CMLS · 2023Article
- Endogenous endophthalmitis due toClinical case reports · 2023Article
- Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe optimal management of patients with endophthalmitis is challenging and includes both intravitreal and, in some cases, systemic antimicrobials. Systemic antimicrobials may be administered either intravenously or orally. In this article we review systemic antimicrobial options currently available for the treatment of types of endophthalmitis and the role of systemic antimicrobials (antibiotics and antifungals) in these treatments. REVIEW: While systemic antimicrobials are not universally utilized in the management of endophthalmitis, they may be helpful in some circumstances. The blood-retinal barrier affects the penetration of systemic medications into the posterior segment of the eye differently; for example, moxifloxacin and imipenem cross the blood-retinal barrier relatively easily while vancomycin and amikacin do not. However, inflammation, including endophthalmitis, may disrupt the blood-retinal barrier, enhancing the penetration of systemic agents into the eye.
conclusionSystemic antimicrobials may be particularly beneficial in patients with certain types of endophthalmitis; as such, they are standard treatment in the management of endogenous endophthalmitis (fungal and bacterial) and also widely used for prophylaxis and treatment of open-globe injuries. Although systemic antimicrobials are used in some patients with acute-onset postoperative endophthalmitis following cataract surgery, the literature generally does not support this practice. It is noted that there are currently no randomized clinical trials demonstrating a benefit of systemic antibiotics for any category of endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.